By utilizing the two AI-resistant cell model MCF-7 LTED and T47D LTED, we revealed that downregulated expression of SERPINA3, an ERα target gene, confers endocrine-resistance to breast cancer cells during AI therapy by enhancing ANKRD11 expression and HDAC3 deacetylase activity. This evidence concerns the gene ANKRD11 and breast carcinoma.